Literature DB >> 32816733

Epidemiological and Clinical Characteristics of International Travelers with Enteric Fever and Antibiotic Resistance Profiles of Their Isolates: a GeoSentinel Analysis.

Stefan H F Hagmann1,2, Kristina M Angelo3, Ralph Huits4, Katherine Plewes5, Gilles Eperon6, Martin P Grobusch7, Anne McCarthy8, Michael Libman9, Eric Caumes10, Daniel T Leung11, Hilmir Asgeirsson12,13, Mogens Jensenius14, Eli Schwartz15,16, Adrian Sánchez-Montalvá17, Paul Kelly18, Prativa Pandey19, Karin Leder20,21, Daniel L Bourque22,23, Yukihiro Yoshimura24, Frank P Mockenhaupt25,26, Perry J J van Genderen27, Silvia Odolini28,29, Patricia Schlagenhauf30, Bradley A Connor31, Davidson H Hamer32,33,34.   

Abstract

Enteric fever, caused by Salmonella enterica serovar Typhi (S Typhi) and S. enterica serovar Paratyphi (S Paratyphi), is a common travel-related illness. Limited data are available on the antimicrobial resistance (AMR) patterns of these serovars among travelers. Records of travelers with a culture-confirmed diagnosis seen during or after travel from January 2007 to December 2018 were obtained from GeoSentinel. Traveler demographics and antimicrobial susceptibility data were analyzed. Isolates were classified as nonsusceptible if intermediate or resistant or as susceptible in accordance with the participating site's national guidelines. A total of 889 travelers (S Typhi infections, n = 474; S Paratyphi infections, n = 414; coinfection, n = 1) were included; 114 (13%) were children of <18 years old. Most individuals (41%) traveled to visit friends and relatives (VFRs) and acquired the infection in South Asia (71%). Child travelers with S Typhi infection were most frequently VFRs (77%). The median trip duration was 31 days (interquartile range, 18 to 61 days), and 448 of 691 travelers (65%) had no pretravel consultation. Of 143 S Typhi and 75 S Paratyphi isolates for which there were susceptibility data, nonsusceptibility to antibiotics varied (fluoroquinolones, 65% and 56%, respectively; co-trimoxazole, 13% and 0%; macrolides, 8% and 16%). Two S Typhi isolates (1.5%) from India were nonsusceptible to third-generation cephalosporins. S Typhi fluoroquinolone nonsusceptibility was highest when infection was acquired in South Asia (70 of 90 isolates; 78%) and sub-Saharan Africa (6 of 10 isolates; 60%). Enteric fever is an important travel-associated illness complicated by AMR. Our data contribute to a better understanding of region-specific AMR, helping to inform empirical treatment options. Prevention measures need to focus on high-risk travelers including VFRs and children.
Copyright © 2020 American Society for Microbiology.

Entities:  

Keywords:  antimicrobial resistance; enteric fever; paratyphoid; travel; typhoid

Year:  2020        PMID: 32816733      PMCID: PMC7577154          DOI: 10.1128/AAC.01084-20

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  34 in total

1.  Imported Cases of Extensively Drug-Resistant Salmonella.

Authors:  Patricia J Simner; Yehudit Bergman; Pranita D Tamma
Journal:  Pediatr Infect Dis J       Date:  2019-12       Impact factor: 2.129

2.  Extensively Drug-Resistant Typhoid - Are Conjugate Vaccines Arriving Just in Time?

Authors:  Jason R Andrews; Farah N Qamar; Richelle C Charles; Edward T Ryan
Journal:  N Engl J Med       Date:  2018-10-18       Impact factor: 91.245

3.  Enteric fever among children: 50 cases in a French tertiary care centre.

Authors:  Virginie Pommelet; Patricia Mariani; Romain Basmaci; Mathieu Tourdjman; Laurence Morin; Jean Gaschignard; Agathe de Lauzanne; Chloé Lemaitre; Stéphane Bonacorsi; Albert Faye
Journal:  J Travel Med       Date:  2018-01-01       Impact factor: 8.490

Review 4.  Typhoid and paratyphoid fever in travellers.

Authors:  Bradley A Connor; Eli Schwartz
Journal:  Lancet Infect Dis       Date:  2005-10       Impact factor: 25.071

5.  Changing Patterns in Enteric Fever Incidence and Increasing Antibiotic Resistance of Enteric Fever Isolates in the United States, 2008-2012.

Authors:  Kashmira A Date; Anna E Newton; Felicita Medalla; Anna Blackstock; LaTonia Richardson; Andre McCullough; Eric D Mintz; Barbara E Mahon
Journal:  Clin Infect Dis       Date:  2016-04-18       Impact factor: 9.079

6.  Emergence of Extensively Drug-Resistant Salmonella Typhi Infections Among Travelers to or from Pakistan - United States, 2016-2018.

Authors:  Kevin Chatham-Stephens; Felicita Medalla; Michael Hughes; Grace D Appiah; Rachael D Aubert; Hayat Caidi; Kristina M Angelo; Allison T Walker; Noël Hatley; Sofia Masani; June Nash; John Belko; Edward T Ryan; Eric Mintz; Cindy R Friedman
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2019-01-11       Impact factor: 17.586

7.  The first Canadian pediatric case of extensively drug-resistant Salmonella Typhi originating from an outbreak in Pakistan and its implication for empiric antimicrobial choices.

Authors:  Waison Wong; Hatem Al Rawahi; Samir Patel; Yvonne Yau; Alireza Eshaghi; Sandra Zittermann; Leah Tattum; Shaun K Morris
Journal:  IDCases       Date:  2019-01-15

8.  Informal genomic surveillance of regional distribution of Salmonella Typhi genotypes and antimicrobial resistance via returning travellers.

Authors:  Danielle J Ingle; Satheesh Nair; Hassan Hartman; Philip M Ashton; Zoe A Dyson; Martin Day; Joanne Freedman; Marie A Chattaway; Kathryn E Holt; Timothy J Dallman
Journal:  PLoS Negl Trop Dis       Date:  2019-09-12

9.  Treatment responses to Azithromycin and Ciprofloxacin in uncomplicated Salmonella Typhi infection: A comparison of Clinical and Microbiological Data from a Controlled Human Infection Model.

Authors:  Celina Jin; Malick M Gibani; Shaun H Pennington; Xinxue Liu; Alison Ardrey; Ghaith Aljayyoussi; Maria Moore; Brian Angus; Christopher M Parry; Giancarlo A Biagini; Nicholas A Feasey; Andrew J Pollard
Journal:  PLoS Negl Trop Dis       Date:  2019-12-26

10.  Phase I of the Surveillance for Enteric Fever in Asia Project (SEAP): An Overview and Lessons Learned.

Authors:  Caitlin Barkume; Kashmira Date; Samir K Saha; Farah Naz Qamar; Dipika Sur; Jason R Andrews; Stephen P Luby; M Imran Khan; Alex Freeman; Mohammad Tahir Yousafzai; Denise Garrett
Journal:  J Infect Dis       Date:  2018-11-10       Impact factor: 5.226

View more
  4 in total

Review 1.  Travel vaccines throughout history.

Authors:  Androula Pavli; Helena C Maltezou
Journal:  Travel Med Infect Dis       Date:  2022-02-12       Impact factor: 6.211

Review 2.  GeoSentinel: past, present and future†.

Authors:  Davidson H Hamer; Aisha Rizwan; David O Freedman; Phyllis Kozarsky; Michael Libman
Journal:  J Travel Med       Date:  2020-12-23       Impact factor: 8.490

Review 3.  Antimicrobial Resistance and Human Mobility.

Authors:  Angel N Desai; Amir M Mohareb; Naomi Hauser; Aula Abbara
Journal:  Infect Drug Resist       Date:  2022-01-13       Impact factor: 4.003

Review 4.  Antimicrobial-resistant bacteria in international travelers.

Authors:  Sushmita Sridhar; Sarah E Turbett; Jason B Harris; Regina C LaRocque
Journal:  Curr Opin Infect Dis       Date:  2021-10-01       Impact factor: 4.915

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.